**Core tip:** In the era of cancer immunotherapy, the roles of radiation therapy (RT) are not limited to the direct killing of cancerous cells but have expanded to immune modulation. Numerous proof-of-concept preclinical studies have proven that combination approaches of RT and immune checkpoint inhibitors (ICIs) are highly promising for many types of cancers, and currently, many related clinical trials are ongoing. Historically, RT was considered ineffective for hepatocellular carcinoma (HCC), but the efficacy of RT in HCC has improved greatly with technical advances. Our goal of this review is to provide a rationale for the combined treatment with RT and ICIs in HCC.

INTRODUCTION
============

Hepatocellular carcinoma (HCC), which is the predominant type of liver cancer, is the fifth most common cancer\[[@B1],[@B2]\]. The incidence of HCC is relatively high in South-East Asia, and that in North America and Western Europe is increasing\[[@B3]\]. Although hepatitis B and C infection are the main causes of HCC, alcohol consumption, liver cirrhosis, non-alcoholic fatty liver disease, aflatoxin exposure, and hereditary disorders such as hemochromatosis and alpha-1-antitrypsin deficiency can be also the etiologies of HCC\[[@B4]-[@B6]\]. The Barcelona Clinic Liver Cancer (BCLC) system recommends various treatment strategies, including curative local modalities, such as resection, liver transplantation, and ablation, and palliative chemoembolization and sorafenib according to the BCLC stage, performance status, and liver function\[[@B7]\]. However, patients with advanced stage HCC have very poor outcomes\[[@B8]\] and novel approaches to greatly improve clinical outcomes are urgently needed.

Cancer immunotherapy has become a game-changer in cancer treatment, and we have witnessed how it has led to a paradigm shift in cancer therapy. Although surgical removal or elimination of tumor cells by chemotherapy or radiotherapy is still a mainstay treatment, the reinvigoration of the antitumor immunity in the tumor microenvironment (TME) is gaining growing attention. Tumors escape from immune surveillance using various mechanisms\[[@B9]\]. Among them, a better understanding of the immune checkpoint mechanism has led to new therapeutic targets for cancer therapy, the so-called immune checkpoint inhibitors (ICIs). Programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) are the main targets of ICIs\[[@B10]\]. To date, beginning with the approval of ipilimumab \[anti-CTLA-4 monoclonal antibodies (mAbs)\] for malignant melanoma in 2011, a number of ICIs, including three anti-PD-1 antibodies (nivolumab, pembrolizumab, and cemiplimab) and three anti-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab), have been approved by the Food and Drug Administration (FDA) for different types of cancers such as melanoma and non-small cell lung cancer\[[@B9]\]. In addition, the use of nivolumab and pembrolizumab has now extended to patients with HCC who have been previously treated with sorafenib.

Radiation therapy (RT) has been used as an essential local treatment modality for a broad range of malignancies for over a century, and its immune-related effects have recently gained extensive attention in the era of immunotherapy\[[@B11],[@B12]\]. Figure [1](#F1){ref-type="fig"} illustrates the modulation of tumor immunity by RT and ICIs. RT has both pro-immunogenic and immunosuppressive effects on immune responses. RT triggers immunogenic cell death, which releases danger-associated molecular patterns (DAMPs) and primes immune cells, including dendritic cells (DCs), in the TME. RT also enhances immune cell infiltration by upregulating the expression of adhesion molecules on endothelial cells and the secretion of cytokines that can recruit cytotoxic T lymphocytes\[[@B13]\]. By contrast, RT directly kills radiosensitive CD8 effector T lymphocytes and preserves the less radiosensitive regulatory T lymphocytes (Tregs)\[[@B14]\]. Moreover, RT-induced production of transforming growth factor-beta (TGF-β) renders the TME more immunosuppressive\[[@B15]\]. RT-induced colony-stimulating factor-1 (CSF-1) also acts in immune suppression mechanisms such as the M2 polarization of tumor-associated macrophages and the recruitment of myeloid-derived suppressor cells (MDSCs)\[[@B16]\]. Furthermore, a substantial increase in the expression of PD-L1 and PD-1 in tumor cells and T lymphocytes, respectively, following RT weakens anti-tumor immunity, providing a rationale for combination treatment with ISIs.

![Modulation of tumor immunity by radiotherapy and immune checkpoint blockade. Radiation-induced cell death results in cytosolic DNA accumulation in the tumor, which in turn activates the production of type I interferon (IFN) genes *via* cGAS/STING pathway. Increased IFN activates antigen presenting cells such as dendritic cells (DCs), which can prime T cells within draining lymph node. IFN also mediates recruitment of effector CD8^+^ T cells capable of killing cancer cells into irradiated tumor sites. Radiation triggers the release of tumor antigens and danger-associated molecular patterns, which can also activate DCs. Radiation-induced secretion of cytokines and chemokines play both pro-immunogenic and immunosuppressive roles in the tumor microenvironment. The antitumor effect of radiation therapy (RT) is frequently hindered by activation of immune checkpoint pathways. Thus, the combination of RT and immune checkpoint inhibitors such as anti-programmed death 1 inhibitor shows a synergistic effect in many types of cancer. The immune checkpoint blockade also enhances RT-induced systemic effect, called abscopal effect, which refers to the regression of an unirradiated tumor. cGAS: Cyclic guanosine monophosphate-adenosine monophosphate synthase; CTLA-4: Cytotoxic T lymphocyte-associated protein 4; IFN: Interferon; LN: Lymph node; MHC: Major histocompatibility complex; PD-1: Programmed death 1; PD-L1: Programmed death-ligand 1; STING: Stimulator of interferon genes; TAA: Tumor-associated antigen; TCR: T-cell receptor; Trex1: Three prime repair exonuclease 1.](WJG-25-2416-g001){#F1}

Numerous preclinical studies have provided convincing evidence that the combination of ICI and RT (iRT) can be more potent than either treatment alone\[[@B17]\]. The benefits of iRT have been reported in head and neck cancer, metastatic melanoma, metastatic pancreas cancer, and lung cancer\[[@B18],[@B19]\], and clinical trials evaluating the outcomes of iRT are now ongoing\[[@B20]\]. The clinical use of immuno-therapy in the form of iRT has been extended to HCC\[[@B21]\], and several ongoing trials are investigating the benefits of immunotherapy for HCC\[[@B22]\]. In this review, we will discuss the basis of immunotherapy and iRT, and their application in HCC. Regarding immunotherapy, we will focus only on the CTLA-4 and PD-1/PD-L1 pathways in this review. Moreover, we will also discuss the future perspectives of immunotherapy and iRT for HCC.

IMMUNE CHECKPOINT INHIBITORS
============================

The immunologic effect on the host has been an intriguing issue for the past several decades in cancer research. To date, a variety of cellular molecules relevant to the activation and inhibition of cancer immunity have been identified (Figure [1](#F1){ref-type="fig"}). Among these molecules, CTLA-4 and PD-1/PD-L1 have been proven to be effective targets for cancer immunotherapy, and their discovery opened a new landscape in cancer treatment\[[@B23],[@B24]\].

CTLA-4 is an immune checkpoint receptor that is upregulated in activated T cells and constitutively expressed in Treg cells, and it negatively regulates the priming phase of the immune response. It outcompetes CD28 stimulatory protein for binding to CD80/CD86 (also called B7-1/2) located on the surface of antigen presenting cells (APCs), including DCs, and the interaction between CTLA-4/CD80 transmits inhibitory signals to T cells. CTLA-4 also facilitates immunosuppression by activating Tregs and upregulating indoleamine 2,3-dioxygenase (IDO) and IL-10 in DCs. Anti-CTLA-4 antibodies were designed to release T cells from the inhibitory signals and reactivate them, resulting in strong antitumor immunity\[[@B25]\]. Ipilimumab, the first humanized anti-CTLA4 mAb, produces remarkable responses in patients with metastatic melanoma\[[@B23]\]. Superior treatment outcomes following combination treatment with ipilimumab and nivolumab (PD-1 inhibitor) have been reported in advanced melanoma, although toxicities were higher with combination treatment than with monotherapy\[[@B26]\].

PD-1, firstly discovered in 1992, is another immune inhibitory receptor for the effector phase of the immune response\[[@B27]\]. It is primarily expressed by mature T cells in peripheral tissues and is also expressed in other immune cells including B Cells, natural killer (NK) cells, Tregs, MDSCs, and DCs. It has high binding affinity to PD-L1 (also called B7-H1), which is broadly expressed in hematopoietic cells such as APCs and MDSCs and non-hematopoietic cells such as parenchymal cells. The PD-1/PD-L1 interaction plays key roles in maintaining immune homeostasis in normal tissues. Tumor cells also express PD-L1, which allows them to escape immune surveillance in the TME. In the TME, antigen-specific T cells produce interferon-gamma (IFN-γ), which in turn induces PD-1 and PD-L1 expression on T cells and tumor cells, respectively. This ligand/receptor binding leads to T-cell exhaustion. Nivolumab was the first PD-1 inhibitor approved by the FDA; it was first approved for melanomas, followed by non-small-cell lung cancer and other cancers. Anti-PD-L1 antibodies such as atezolizumab, durvalumab, and avelumab were also developed to block the PD-1/PD-L1 axis and are now on the market.

ICI IN HCC
==========

HCC has distinct characteristics compared to those of other cancers regarding the application of ICIs. Although a variety of etiologies link to the development of HCC, viral infection comprises the largest proportion, particularly in HBV and HCV epidemic areas\[[@B28]\]. The chronic inflammatory status stimulated by viral infection can effectively exhaust immune systems, thereby facilitating immune tolerance. Furthermore, the liver is an organ into which large amounts of antigens from the intestines drain via the portal vein, which also attenuates the immune surveillance system\[[@B29],[@B30]\]. Indeed, pre-clinical and clinical studies have indicated that advanced HCC has a highly immunosuppressive TME, as indicated by intratumor CD8+ T cell exhaustion and inefficient T cell infiltration\[[@B31],[@B32]\].

Hepatic immune tolerance is mainly mediated by specialized APCs such as resident DCs, liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs), and hepatic stellate cells (HSCs), as well as Treg cells and MDSCs\[[@B33]\]. They express inhibitory cytokines and immune checkpoint molecules including CTLA-4, PD-1, TIM-3, LAG-3 and BTLA\[[@B34]\]. Among them, PD-1 expression is high on effector CD8+ T cells within tumors of patients with HCC\[[@B35]\], which is associated with poor disease progression and postoperative recurrence\[[@B36]\]. Overexpression of PD-L1 is also seen on tumor cells as well as non-parenchymal liver cells such as KCs and LSECs, predicting tumor aggressiveness and postoperative recurrence in HCC\[[@B37]\]. In this background, ICIs were anticipated to be highly effective in HCC and therapeutic efficacy of CTLA-4 and PD-1/PD-L1 targeted therapies was clinically evaluated in HCC. Treatment-related hepatic toxicity is one of the most concerning issues when applying ICIs to patients with HCC because most patients with HCC have liver cirrhosis and are usually more vulnerable to systemic therapeutics than those with other malignancies.

The first study to evaluate the treatment outcomes of a CTLA-4 inhibitor, tremelimumab, was conducted in HCV-related HCC. This pilot clinical trial found a partial response rate of 17.6% and disease control rate of 76.4\[[@B38]\]. Interestingly, tremelimumab showed both anti-tumoral and anti-viral effects. Treatment-related hepatic toxicities were observed in approximately one-half of the patients, but they were all reversible. This success with tremelimumab encouraged the testing of other ICIs in HCC. In the CheckMate 040 trial, the feasibility of a PD-1 inhibitor, nivolumab, was evaluated in patients with HCC, finding an overall response rate of 15-20% with no severe toxicity\[[@B39]\]. Another phase 2 trial (KEYNOTE-224) investigating the efficacy of pembrolizumab in patients with advanced HCC who had been previously treated with sorafenib\[[@B40]\]. In this trial, the objective response rate was 17% and 12-mo progression-free survival and overall survival were 28% and 54%, respectively. While safety of combination treatment with PD-1 and CTLA-4 inhibitors could be proven in phase I/II, efficacy should be proven in phase III\[[@B41]\]. CheckMate-459 (NCT02576509) trial is an ongoing phase III trial to evaluate the role of nivolumab in frontline setting for advanced HCC\[[@B42]\]. Another ongoing phase III trial, Keynote-240 trial (NCT02702401), is to investigate the benefit of pembrolizumab in previously treated advanced HCC\[[@B43]\]. Most recently, Merck released update on Keynote-240 study. They announced that the patients who have been treated with pembrolizumab had superior OS to those treated with placebo, but the superiority failed to reach pre-specified statistical significance \[HR=0.78 (95%CI: 0.611-0.998); *P* = 0.0238\]\[[@B44]\]. Although they failed to meet primary endpoints, favorable OS in pembrolizumab-treated group suggests that more evidence be needed to confirm the role of this drug. The final result from Keynote-240 and other ongoing trials are awaited. The combination treatment with durvalumab and tremelimumab showed better outcomes compared to monotherapy, but it showed higher toxicity rates. Based on the phase I/II trial outcomes, a large phase III trial, the HIMALAYA study, is ongoing to examine the feasibility of durvalumab and tremelimumab as first-line treatment for advanced HCC\[[@B45]\].

RADIOTHERAPY IN HCC
===================

Traditionally, external beam RT (EBRT) has been limited role in the treatment of HCC\[[@B46]\]. Because of several obstacles facing the use of liver EBRT such as respiratory motion control, target delineation of hepatoma, and difficulty in image-guidance, few institutions had the technical ability to perform EBRT for patients with HCC\[[@B47]\]. Therefore, the role of EBRT was restricted in the palliation of metastatic HCC. In recent years, there has been growing interest in the use of EBRT in patients with HCC\[[@B46],[@B48]\]. The recent technical advances ensure that high doses of radiation will be precisely delivered to the target in the liver while sparing the normal tissue\[[@B8]\]. As a result, EBRT has been utilized increasingly and practice guidelines of EBRT in HCC have been presented especially in Asian area\[[@B49],[@B50]\].

The use of EBRT for primary HCC has various aims, including ablation of HCC; consolidation of other local treatments, mainly chemoembolization; bridging to liver transplantation; salvation from disease refractory to other treatment; and palliation\[[@B48],[@B50]-[@B52]\]. Specifically, as higher doses of irradiation are widely attempted, stereotactic body RT (SBRT) or hypofractionated EBRT with ablative doses is increasingly used, with comparable local control compared to that with radiofrequency ablation\[[@B53]-[@B56]\]. Proton beam therapy (PBT) is another optimized EBRT tool for high-dose irradiation\[[@B57],[@B58]\]. The physical properties of PBT with no exit dose minimize the integral doses in the normal liver parenchyma\[[@B59],[@B60]\]. Therefore, PBT enables dose escalation without increasing the risk of radiation-induced liver toxicities, as evidenced by retrospective studies reporting that PBT showed excellent local control and low incidences of toxicities\[[@B57],[@B58]\]. RT challenged the treatment guidelines of the BCLC system for HCC with macroscopic vascular invasion, which recommend sorafenib\[[@B8],[@B61]\]. Recently, Yoon et al\[[@B62]\] showed in a phase II randomized controlled trial that the outcomes of chemoembolization followed by EBRT were superior to those of sorafenib in patients with HCC with macrovascular invasion, providing improved progression-free survival, objective response rate, time to progression, and overall survival. With the accumulation of evidence regarding the benefits of RT for primary HCC, other guidelines for the treatment of primary HCC have extended the range for the application of RT\[[@B50]\].

Aside from EBRT, selective internal RT (SIRT) using yttrium-90 (^90^Y) microspheres is also increasingly utilized in the treatment of primary HCC\[[@B63]\]. SIRT, also known as radioembolization, is a form of brachytherapy in which microspheres loaded with ^90^Y that emit high-energy beta radiation are administrated via a microcatheter positioned within the hepatic artery\[[@B64]\]. Because of the limited penetration depth of 2.5 mm of the beta-radiation, this approach spares much of normal liver tissue. The clinical application of SIRT is largely limited because of the lack of clinical evidence, but its roles in tumor control and immune activation are actively being investigated\[[@B65]\].

The role of palliative RT for HCC metastases has been expanded as well. Although the development of new systemic agents has improved the overall survival of patients with cancer, efficacious local modalities that palliate symptoms are frequently needed as the disease progresses\[[@B66]\]. In metastatic HCC, the need for palliative care has been raised, and technological advances have led to an increase in the use of palliative RT\[[@B67]\]. Bone metastasis from a primary HCC represents the type of soft tissue formation that requires high-dose irradiation for the long-term control of the tumor and symptoms\[[@B68]\] and in retrospective studies, the use of SBRT or hypofractionated RT with high doses was proven to be an effective way to control painful bone metastases from HCC\[[@B67],[@B69],[@B70]\]. This trend would be in accord with the scheme for iRT in which hypofractionated RT is preferred for immune boosting, as described below.

COMBINATION OF RT AND ICIs
==========================

Synergistic effects of RT and ICIs
----------------------------------

Although ICIs have recently revolutionized cancer treatment, overall response rates remain around 20%, with much room for further improvement. RT is one of the most encouraging strategies that can be combined with ICIs to improve treatment outcomes because of its pro-immunogenic properties. On the other hand, the addition of ICIs could help overcome radiation resistance caused by radiation-induced immuno-suppressive effects. These synergistic effects of iRT have been proven in numerous preclinical studies and clinical settings\[[@B11],[@B18],[@B19],[@B71],[@B72]\]. Demaria et al\[[@B73]\] provided the first evidence of a synergistic effect when examining RT and CTLA-4 blockade using a murine 4T1 mammary carcinoma model; the survival of mice harboring a poorly immunogenic 4T1 tumor was not affected by CTLA-4 blockade alone but was significantly increased when combined with RT. Subsequently, the synergy between RT and PD-1 blockade was intensively investigated in preclinical settings\[[@B74]-[@B77]\]. For example, Zeng et al\[[@B74]\] showed that stereotactic radiation combined with anti-PD-1 antibodies markedly increased the survival of mice with intracranial gliomas with increased CD8^+^ T cells and decreased Treg cell infiltration. Another preclinical study using syngeneic mouse models revealed that PD-L1 blockade exerted a synergistical anti-tumor immunity with RT *via* MDSC reduction and cytotoxic T cell activation\[[@B78]\].

These lines of preclinical evidence provide a strong rationale for the use of combined iRT for cancer treatment, and numerous clinical evaluations are currently ongoing. A phase III trial (CA184-043) evaluating RT and ipilimumab in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy has been conducted; post hoc subgroup analysis revealed a survival benefit with anti-CTLA-4 ipilimumab\[[@B79]\]. The efficacy of combining PD-1/PD-L1 blockade with RT has been tested more frequently in the clinical setting. A recent phase III PACIFIC trial for patients with unresectable stage III non-small lung cancer (NSCLC) receiving chemoradiation showed significant improvement of progression-free survival with anti-PD-L1 durvalumab *vs* placebo (median survival 16.8 mo *vs* 5.6 mo)\[[@B80]\]. According to a recent update of the PACIFIC trial, overall survival was also improved in the durvalumab group *vs* placebo group (2-year overall survival 66.3% *vs* 55.6%)\[[@B81]\]. The secondary analysis of the KEYNOTE-001 trial that studied patients with locally advanced or metastatic NSCLC treated with anti-PD-1 pembrolizumab revealed that patients who had previously received RT benefited from pembro-lizumab compared to patients without RT in terms of improved progression-free survival and overall survival with pembrolizumab\[[@B82]\].

RT is a type of local treatment but is also believed to induce systemic effects. An RT-induced systemic effect, called an "abscopal effect," refers to the remission of a tumor outside the RT field. Because it was first reported in 1953\[[@B83]\], only anecdotal clinical evidence was reported for several decades\[[@B84]\]. However, in the era of cancer immunotherapy, abscopal effects are increasingly being reported when RT is given concomitantly with ICIs. Demaria et al\[[@B85]\] first showed evidence that an RT-induced abscopal effect is an immune-mediated response using a syngeneic mouse model bearing two tumors. Thereafter, numerous preclinical results using ICIs were reported\[[@B86]-[@B88]\]. Using PD-1 knockout mice, Park et al\[[@B88]\] showed that PD-1 blockade is a promising strategy to potentiate abscopal effects as well as anti-tumor effects caused by stereotactic ablative RT. In the clinical setting, Postow et al\[[@B89]\] reported the case of an abscopal effect in a patient with melanoma treated with anti-CTLA-4 ipilimumab and RT. Since then, several studies have reported that combined immunotherapy boosts the abscopal effects of RT, although the optimal dose/fraction size is still a matter of debate\[[@B84],[@B90]-[@B92]\].

As described above, RT modulates immunity in the TME directly or indirectly, and a thorough understanding is important to design the optimal settings for iRT. RT exerts immunostimulatory effects by increasing CD8^+^ effector T cells\[[@B93]\] and type I IFN is a key modulator for their recruitment in response to RT\[[@B94]\]. The production of type I IFN required for anti-tumor immunity is mediated by stimulator of interferon genes (STING), and the upstream cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) signaling pathways are initiated by sensing tumor-derived cytosolic DNA (Figure [1](#F1){ref-type="fig"})\[[@B95]-[@B97]\]. On the other hand, RT exerts immune-inhibitory effects by upregulating PD-L1 expression or secreting cytokines such as TGF-β, which contributes to radio-resistance\[[@B98],[@B99]\]. The balance between two opposite immune reactions depends on the radiation dose schemes, sequences between RT and ICIs, and treatment volume of radiation\[[@B100]\]. Therefore, these parameters need to be established in order to determine the optimal RT conditions that reach the maximum synergistic effect with ICIs.

Treatment sequences
-------------------

When RT is given, ICIs can be administered before RT, after RT, or concurrently. Several preclinical studies have been performed to determine the optimal sequences of RT and ICIs. Dovedi et al\[[@B77]\] showed the concurrent administration of anti-PD-L1 mAb with RT of 2 Gy × 5 was more effective than their sequential application. On the other hand, another study showed that anti-CTLA-4 antibodies were most effective when given prior to RT\[[@B101]\], which reflects the function of CTLA-4 blockade in Treg depletion. Single large doses (\> 20 Gy) of RT followed by anti-CTLA-4 also enhanced anti-tumor immunity in a Lewis lung carcinoma mouse model\[[@B102]\] and a mesothelioma mouse model\[[@B103]\], suggesting that dose and fraction size may also have an effect. A concurrent regimen for anti-PD-L1 and RT was also effective in a bladder cancer model\[[@B104]\]. Further retrospective or prospective studies are required to elucidate the optimal timing of RT that maximizes outcomes in patients co-treated with RT and ICIs.

Radiation dose and fractionation
--------------------------------

It is widely accepted that SBRT or hypofractionated RT may be more immunogenic than conventional fractionated RT with 2 Gy per day. Lugade et al\[[@B105]\] showed that a single dose of 15 Gy boosted the immune reaction more effectively than a fractionated dose of 3 Gy × 5 in a B16 murine melanoma mouse model. Regarding the combination with ICIs, Dewan et al. reported that an 8 Gy × 3 regimen showed better local tumor control and a systemic abscopal effect than two other regimens, 20 Gy × 1 and 6 Gy × 5, plus anti-CTLA-4 mAb in a TSA mouse breast carcinoma model\[[@B86]\]. A recent study by Vanpouille-Box et al\[[@B106]\] provided an important mechanistic clue regarding the modulation of the immunogenic effect by different dose/fractionation schemes. They showed that 8 Gy × 3 but not a single 30 Gy dose when co-treated with anti-CTLA-4 antibodies induced abscopal responses with increased IFN-β production *via* the cGAS/STING pathway. A single radiation dose between 12 and 18 Gy upregulates the DNA exonuclease TREX, which in turn degrades cytoplasmic double-stranded DNA, resulting in turning off RT-induced immune stimulation. Thus, the use of a dose per fraction above 12 Gy for synergy with ICIs needs to be reconsidered.

Treatment volume
----------------

Draining lymph nodes (LNs) where APCs present antigens to T cells play a critical role in PD-1/PD-L1 therapy\[[@B75],[@B107]\]. However, paradoxically, draining LNs are usually suspected to contain cancer cells as well as immune cells, which encourages radiation oncologists to encompass them in the RT field. In the setting of combination treatment with ICIs, the benefit of an RT target volume that includes draining LNs should be weighed against the risk of loss of tumor antigen-specific immune cells that help to reinvigorate anti-tumor immunity. Further studies to clarify the need for the modification of target delineation in the iRT setting may be warranted.

PRECLINICAL DATA AND ONGOING TRIALS FOR HCC
===========================================

As described above, there are numerous studies and ongoing trials regarding the synergistic efficacy of ICIs and RT in various cancer types such as melanoma, head-and-neck cancer, non-small cell lung cancer, colorectal cancer, sarcoma, and renal cell carcinoma\[[@B11]\]. However, the studies on the combination effect in HCC are still underway, and just a few results have been reported to date. To the best of our knowledge, only two preclinical studies have been conducted to investigate the efficacy and the mechanism of ICIs and RT in murine HCC models\[[@B108],[@B109]\]. Kim et al\[[@B108]\] showed that RT upregulated PD-L1 expression via IFN-γ/STAT3 signaling in the murine HCa-1 HCC cell line. The authors showed that the combination of anti-PD-L1 and RT of 10 Gy significantly suppressed Hca-1 tumor growth in syngeneic C3H mice and improved the survival of tumor-bearing mice compared to those with anti-PD-L1 alone or RT alone. The combination treatment increased the infiltration of effector CD8^+^ T cells and enhanced RT-induced apoptotic death within tumor tissue. These results suggest that iRT may hold promise as a potential strategy for HCC treatment. Another preclinical study supported the synergistic effect of the SBRT and anti-PD-1 combination in an orthotopic murine HCC model\[[@B109]\]. A Hep-55.1C tumor was injected into the liver right lobe, and 30 Gy in 3 fractions was delivered using a specialized irradiation system called the Small Animal Radiation Research Platform (SARRP). The combination of SBRT and anti-PD-1 antibodies markedly suppressed tumor growth and improved survival with increased infiltration of CD8^+^ cytotoxic T cells within the tumor.

There are only a limited number of studies on the combination effect of ICIs and RT in patients with HCC in the clinical setting. Kim et al\[[@B110]\] reported the clinical significance of the soluble PD-L1 level in blood samples from patients with HCC. The authors showed that EBRT significantly increased the soluble PD-L1 level and that a higher soluble PD-L1 level at 1 mo after EBRT was significantly associated with early lung metastasis and poor overall survival. Even though PD-1/PD-L1 therapy was not tested in this study, these findings support the rationale that iRT might be a promising therapeutic strategy in patients with HCC. In addition to the EBRT, the immune responses by the SIRT are under investigation. SIRT allows delivery of high-dose radiation up to 170 Gy penetrating the tissue with depth ranging from 2.5 to 11 mm\[[@B111]\]. Therefore, it was hypothesized that SIRT may have robust immunogenic effect by its similarity with high-dose EBRT with single fraction. However, there is very few literatures and only a case report showing the enhancement of the antitumoral immune response by the combination of nivolumab and SIRT with ^90^Y\[[@B112]\]. An analysis of tumor-infiltrating leukocytes isolated from patients with HCC after ^90^Y radioemboliztion revealed SIRT resulted in higher tumor infiltration of CD8^+^ T cells, and CD8^+^ and/or CD56^+^ NK cells and higher expression of tumor necrosis factor-α on both the CD8 and CD4 T cells and APCs in peripheral blood\[[@B65]\]. These implied that SIRT with ^90^Y enabled the activation of both local and systemic immune and potential of synergy by combination with ICI. There are needs for clinical data regarding the iRT and now several ongoing clinical trials are being conducted to investigate the efficacy of iRT using various ICIs and EBRT or SIRT for patients with HCC. The trials registered in [www.ClinicalTrials.gov](www.ClinicalTrials.gov) are listed in Table [1](#T1){ref-type="table"}.

###### 

On-going clinical trials for combination of immune checkpoint inhibitor and radiation

  **NCT number**   **Institution**       **Phase**   **Disease**                                                                        **Intervention**                                    **Estimated enrollment**   **Primary endpoint**
  ---------------- --------------------- ----------- ---------------------------------------------------------------------------------- --------------------------------------------------- -------------------------- --------------------------------------------
  NCT03482102      United States (MGH)   II          Locally advanced/ unresectable or metastatic disease HCC or biliary tract cancer   Experimental: Tremelimumab + Durvalumab + EBRT      70                         Best overall response rate
  NCT03203304      United States (UCh)   I           HCC                                                                                SBRT Nivolumab → +/- ipilimumab + SBRT (8 Gy × 5)   50                         Number of participants with adverse events
  NCT03316872      Canada (UHN)          II          HCC showing progression after sorafenib                                            Pembrolizumab + SBRT                                30                         Overall response rate
  NCT03812562      United States (NU)    I           HCC intended to be resected                                                        ^90^Y SIRT → Nivolumab                              12                         Recurrence rate
  NCT03033446      Singapore (NCC)       II          HCC not suitable for resection or transplant                                       ^90^Y SIRT → Nivolumab                              40                         Response rate
  NCT02837029      United States (NU)    I/Ib        HCC stage IIIA - IVB                                                               ^90^Y SIRT → Nivolumab                              35                         Maximum tolerated dose
  NCT03099564      United States (UNC)   I           HCC                                                                                ^90^Y SIRT + Pembrolizumab                          30                         Progression-free survival

MGH: Massachusetts General Hospital; HCC: Hepatocellular carcinoma; EBRT: External beam radiotherapy; UCh: University of Chicago; SBRT: Stereotactic body radiotherapy; UHN: University Health Network; NU: Northwestern University; SIRT: Selective internal radiation therapy; NCC: National Cancer Center; UNC: University of North Carolina.

CONCLUSION
==========

The advent of immunotherapy using ICIs had a great impact on melanoma treatment and is now expanding to the treatment of gastrointestinal malignancies, including HCC. Although the use of iRT in HCC treatment is anticipated, there remain many issues to be investigated. First, ICIs should not be considered the best partners to use with RT in HCC. Aside from ICIs, other immunotherapeutic strategies such as cytokine-induced killer cells or gene therapy using adenoviral vectors have already been assessed in patients with HCC\[[@B113],[@B114]\]. The potential of IL-12 with RT was tested in a murine model, demonstrating that the combined therapy of RT and IL-12 showed better tumor regression compared to each treatment alone; however, this has not been evaluated in the clinical setting yet\[[@B115]\].

Another issue is that an optimized RT methodology for use in combination with ICIs has not been established. Although large amounts of preclinical and clinical data suggest optimal schemes for dose-fractionation, the timing of RT, and target delineation as described above, there is no general consensus that can be applied in the clinic. Further efforts are needed to understand the nature of RT-induced immune responses. In addition, RT-induced lymphopenia may suppress reinvigoration by ICIs, so a specialized RT protocol that can minimize lymphopenia needs to be newly designed for iRT\[[@B116]\]. The combination of ICIs and particle beam therapies is an emerging research field. Because of its dosimetric benefits, particle beam therapy can potentially prevent lymphopenia as well as save the normal liver. The immunologic effects of particle beam therapy are being investigated in other types of cancers such as NSCLC\[[@B117]\]. To date, the clinical trials to assess iRT have been focused on the treatment of primary HCC. However, iRT can potentially be effective in systemic disease control *via* abscopal effects\[[@B84]\]. As with other types of cancers in which the application of iRT for metastatic disease has been tested, iRT for the control of metastatic HCC can be considered a future new therapeutic strategy.

Finally, the appropriate selection of good candidates for iRT is required to improve the outcomes in patients with HCC. PD-L1 expression is a predictive biomarker for PD-1/PD-L1 blockade in patients with NSCLC, but it has not been tested in patients with HCC. Tumor mutation burden and infiltration of effector T lymphocytes are emerging biomarkers\[[@B118]\], but they also have not been evaluated in HCC. Next-generation sequencing-based profiling of tumor mutation burden, immune gene expression signatures, T-cell receptor repertoire, T-cell-inflamed gene expression, and the microbiome could help to predict the suitability of patients with HCC for iRT\[[@B118],[@B119]\]. Such genetic information is useful for predicting not only the susceptibility to ICIs but also the individual radiation sensitivity\[[@B120]-[@B122]\]. Therefore, further efforts to identify the biomarkers to guide the selection of patients with HCC who are appropriate for iRT are needed.

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: South Korea

Peer-review report classification

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

Peer-review started: February 22, 2019

First decision: March 27, 2019

Article in press: April 19, 2019

P-Reviewer: Edeline J, Que JY S-Editor: Ma RY L-Editor: A E-Editor: Zhang YL

[^1]: Author contributions: All authors equally contributed to this paper in the conception and design of the study; literature review and analysis; drafting, critical revision, and editing; and final approval of the final version.

    Corresponding author: Hee Chul Park, MD, PhD, Full Professor, Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea. <hee.ro.park@samsung.com>

    Telephone: +82-2-34012616 Fax: +82-2-34102619
